CRVL 📈 CorVel - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2210061097
CRVL: Claims Management, Healthcare Solutions, Network Services, Patient Management
CorVel Corporation operates at the intersection of healthcare and technology, providing a suite of solutions designed to manage workers' compensation, auto, liability, and health claims. By leveraging advanced technologies such as artificial intelligence, machine learning, and natural language processing, the company enhances the management of care episodes and associated healthcare costs. This approach enables more efficient and effective claims processing, ultimately reducing costs for clients.
The company's network solutions services encompass a broad range of offerings, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, and facility claim review, among others. Additionally, CorVel provides professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services. Its Medicare solutions are also tailored to meet the specific needs of clients navigating the complexities of Medicare claims. By providing these comprehensive services, CorVel helps clients optimize their healthcare spending and improve patient outcomes.
CorVel's patient management services are designed to support the entire care continuum, from initial claims management to ongoing case management and vocational rehabilitation. The company's 24/7 nurse triage service provides patients with immediate access to medical guidance and support, while its utilization management and life care planning services help ensure that patients receive the most appropriate and cost-effective care. Furthermore, CorVel's claims processing services for self-insured payors enable clients to efficiently manage property and casualty insurance claims. By offering these services, CorVel assists employers, third-party administrators, insurance companies, and government agencies in managing medical costs and monitoring the quality of care associated with healthcare claims.
With a history dating back to 1987, CorVel Corporation is a well-established player in the healthcare services industry. Headquartered in Fort Worth, Texas, the company has developed a reputation for delivering innovative solutions that address the complex needs of its clients. As a publicly traded company listed on the NASDAQ exchange under the ticker symbol CRVL, CorVel is committed to transparency and accountability in its operations. With a focus on leveraging technology to drive efficiency and improve patient outcomes, CorVel is poised to continue playing a key role in the evolving healthcare landscape.
Additional Sources for CRVL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CRVL Stock Overview
Market Cap in USD | 6,258m |
Sector | Financial Services |
Industry | Insurance Brokers |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1991-06-28 |
CRVL Stock Ratings
Growth 5y | 96.4% |
Fundamental | 68.8% |
Dividend | - |
Rel. Strength Industry | 754 |
Analysts | - |
Fair Price Momentum | 412.45 USD |
Fair Price DCF | 110.04 USD |
CRVL Dividends
No Dividends PaidCRVL Growth Ratios
Growth Correlation 3m | 62.7% |
Growth Correlation 12m | 88.4% |
Growth Correlation 5y | 93.8% |
CAGR 5y | 32.29% |
CAGR/Mean DD 5y | 2.60 |
Sharpe Ratio 12m | 1.05 |
Alpha | 16.06 |
Beta | 0.84 |
Volatility | 35.07% |
Current Volume | 165k |
Average Volume 20d | 51.7k |
As of December 22, 2024, the stock is trading at USD 345.72 with a total of 165,030 shares traded.
Over the past week, the price has changed by -1.78%, over one month by -2.68%, over three months by +8.96% and over the past year by +43.93%.
Yes, based on ValueRay Fundamental Analyses, CorVel (NASDAQ:CRVL) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 68.75 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRVL as of December 2024 is 412.45. This means that CRVL is currently undervalued and has a potential upside of +19.3% (Margin of Safety).
CorVel has no consensus analysts rating.
According to ValueRays Forecast Model, CRVL CorVel will be worth about 456.2 in December 2025. The stock is currently trading at 345.72. This means that the stock has a potential upside of +31.96%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 456.2 | 32% |